Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
9mLilly has sued 11 retatrutide sellers, FDA has sent warning letters, and Australia's regulator found a 'retatrutide' vial full of semaglutide. Here's the timeline and what it means if you're considering retatrutide.
7mPositive TRIUMPH-2 and TRIUMPH-3 results did not produce a 2026 filing. Lilly says the remaining work is in the CMC and manufacturing package.
8mGHK-Cu is not a magic skin fix. It is a copper peptide with a real research trail behind collagen support, tissue remodeling, and wound healing.
9mPeptides are not only treatment candidates anymore. New constrained ligands may help doctors see the tumor microenvironment more clearly, which changes how researchers think about diagnostics, targeting, and drug design.
8mMost people who take NAD+ daily wonder whether they should cycle it. The answer isn't black and white — it depends on your dose, delivery method, and goals. Here's what the research and community experience actually suggest.
12mRetatrutide is Lilly's investigational GIP/GLP-1/glucagon triple agonist. This hub covers what it is, what the trials actually reported about dosing and weight loss, how vial math works, where approval stands, and links to every retatrutide guide on PeptIQ.io.
Also available at /blog for legacy links.